Leflunomide: long-term clinical experience and new uses

Bibliography

• WOOLF AD, PFLEGER B: Burden of major musculoskeletal conditions. Bull. World Health Organ. (2003) 81(9):646–656.
   PubMed Web of Science ®Google Scholar
• FRIES JF, WILLIAMS CA, MORFELD D, SINGH G, SIBLEY J: Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. (1996) 39(4):616–622.
   PubMed Web of Science ®Google Scholar
• WILES NJ, LUNT M, BARRETT EM et al.: Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. (2001) 44(5):1033–1042.
   PubMed Web of Science ®Google Scholar
• JOBANPUTRA P, WILSON J, DOUGLAS K, BURLS A: A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (2004) 43(2):206–210.
   PubMed Web of Science ®Google Scholar
• SOKKA T, PINCUS T: Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. Rheumatol (2002) 29(12):2521–2524.
   Web of Science ®Google Scholar
• WOLFE F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin. Rheumatol. (1995) 9(4):619–631.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN RM, IQBAL I, STERN RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin. Drug Sal: (2004) 3(5):391–403.
   PubMedGoogle Scholar
• American College of Rheumatology Hotline: FDA Meeting March 2003: Update on the Safety of NewDrugs for Rheumatoid Arthritis. Part II: CHF, Infection and other Safety Issues (2003).
   Google Scholar
• JONES G, CROTTY M, BROOKS P Interventions for psoriatic arthritis (Cochrane review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2001.
   Google Scholar
• ••This meta-analysis emphasises the limitednature of data supporting the use of DMARDs in PsA.
   Google Scholar
• BARTLETT RR, BRENDEL S, ZIELINSKI T, SCHORLEMMER HU: Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant. Proc. (1996) 28(6):3074–3078.
   PubMed Web of Science ®Google Scholar
• FOX RI, HERRMANN ML, FRANGOU CG, WAHL GM, MORRIS RE, KIRSCHBAUM BJ: How does leflunomide modulate the immune response in rheumatoid arthritis? BioDrugs (1999) 12(4):301–315.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the mechanism of action of leflunomide.
   Google Scholar
• CHERWINSKI HM, COHN RG, CHEUNG P et al.: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. I Pharmacol Exp. Ther. (1995) 275(2):1043–1049.
   PubMed Web of Science ®Google Scholar
• GREENE S, WATANABE K, BRAATZ-TRULSON J, LOU L: Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol (1995) 50(6):861–867.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON RA, YEA CM, ROBSON PA et al.: Dihydroorotate dehydrogenase is a high affinity binding protein for All 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. (1995) 270(38):22467–22472.
   PubMed Web of Science ®Google Scholar
• ROCKEMANN K, FAIRBANKS LD, CARREY EA et al.: Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. I Biol. Chem. (1998) 273(34):21682–21691.
   Web of Science ®Google Scholar
• CUTOLO M, SULLI A, GHIORZO P, PIZZORNI C, CRAVIOTTO C, VILLAGIO B: Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(4):297–302.
   PubMed Web of Science ®Google Scholar
• SIEMASKO KF, CHONG AS, WILLIAMS JW, BREMER EG, FINNEGAN A: Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation (1996) 61:635–642.
   PubMed Web of Science ®Google Scholar
• URUSHIBARA M, TAKAYANAGI H, KOGA T et al.: The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells cl Arthritis Rheum. (2004) 50(3):794–804.
   Google Scholar
• ROZMAN B: Clinical pharmacokinetics ofleflunomide. Clin. Pharmacokinet. (2002) 41(6): 421–430.
   PubMed Web of Science ®Google Scholar
• PRAKASH A, JARVIS B: Leflunomide: a review of its use in active rheumatoid arthritis. Drugs (1999) 58(6):1137–1164.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. (1999) 42(7):1322–1328.
   PubMed Web of Science ®Google Scholar
• OSIRI M, SHEA B, ROBINSON V et al: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. Rheumatol (2003) 30(6):1182–1190.
   Web of Science ®Google Scholar
• •A meta-analysis of data concerning leflunomide's efficacy in RA.
   Google Scholar
• SMOLEN JS, EMERY P, KALDEN JR et al.: The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic therapy. J. Rheumatol (2004) 71 (Suppl.):13–20.
   Google Scholar
• STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. (1999) 159(21):2542–2550.
   PubMed Web of Science ®Google Scholar
• •A pivotal Phase III trial of leflunomide versus the gold standard for RA therapy, methotrexate.
   Google Scholar
• SIVA C, EISEN SA, SHEPHERED R et al: Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum. (2003) 49(6):745–751.
   PubMed Web of Science ®Google Scholar
• VAN RIEL PL, SMOLEN JS, EMERY P et al.: Leflunomide: a manageable safety profile. Rheumatol (2004) 71 (Suppl.):21–24.
   Google Scholar
• •A thorough review of adverse events associated with leflunomide and how to manage them.
   Google Scholar
• FIEHN C, ROCHEL E, HO AD, MAX R: Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEE Ann. Rheum. Dis. (2004) 63(6):746–747.
   PubMed Web of Science ®Google Scholar
• POOR G, STRAND V: Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatology (2004) 43(6)744–749.
   Google Scholar
• MLADENOVIC V, DOMLJAN Z, ROZMAN B et al.: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, Phase II study. Arthritis Rheum. (1995) 38(11):1595–1603.
   PubMed Web of Science ®Google Scholar
• CANNON GW, KREMER JM: Leflunomide. Rheum. Dis. OM North Am. (2004) 30(2):295–309.
   PubMed Web of Science ®Google Scholar
• MICELI-RICHARD C, DOUGADOS M: Leflunomide for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. (2003) 4(6):987–997.
   PubMed Web of Science ®Google Scholar
• SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet (1999) 353(9149):259–266.
   PubMed Web of Science ®Google Scholar
• KALDEN JR, SCOTT DL, SMOLEN JS et al.: Improved functional ability in patients with rheumatoid arthritis-longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J. Rheumatol (2001) 28(9):1983–1991.
   PubMed Web of Science ®Google Scholar
• SCOTT DL, SMOLEN JS, KALDEN JR et al.: Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. (2001) 60(10):913–923.
   PubMed Web of Science ®Google Scholar
• STRAND V, TUGWELL P, BOMBARDIER C et al: Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. (1999) 42(9):1870–1878.
   PubMed Web of Science ®Google Scholar
• COHEN S, CANNON GW, SCHIFF M et al: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. (2001) 44(9):1984–1992.
   PubMed Web of Science ®Google Scholar
• EMERY P, BREED VELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (2000) 39(6):655–665.
   PubMed Web of Science ®Google Scholar
• SCOTT DL, STRAND V: The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology (2002) 41(8):899–909.
   Google Scholar
• REECE RJ, KRAAN MC, RADJENOVIC A et al: Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum. (2002) 46(2):366–372.
   PubMed Web of Science ®Google Scholar
• SHARP JT, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized clinical trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigator's Group. Arthritis Rheum. (2000) 43(3):495–505.
   PubMed Web of Science ®Google Scholar
• LARSEN A, KVIEN TK, SCHATTENKIRCHNER M et al: Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand. Rheumatol (2001) 30(3):135–142.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE D, KALDEN J, SCOTT D, SMOLEN J, STRAND V: Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann. Rheum. Dis. (2004) 63(6):737–739.
   PubMed Web of Science ®Google Scholar
• ••Documents the ability of leflunomide tohalt disease progression in some patients.
   Google Scholar
• KALDEN JR, SCHATTENKIRCHNER M, SORENSEN H et al: The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study. Arthritis Rheum. (2003) 48(6):1513–1520.
   PubMed Web of Science ®Google Scholar
• ••Long-term data from extensions ofleflunomide clinical trials.
   Google Scholar
• KALDEN JR, SMOLEN JS, EMERY P et al.: Leflunomide in combination therapy. Rheumatol. (2004) 71(Suppl.):25–30.
   Google Scholar
• KREMER JM, GENOVESE MC, CANNON GW et al: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2002) 137(9):726–733.
   PubMed Web of Science ®Google Scholar
• KREMER JM, GENOVESE MC, CANNON GW et al: Combination leflunomide and methotrexate (1VITX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial../. Rheumatol. (2004) 31(8):1521–1531.
   Google Scholar
• CHUNG C, MALLON C, SPADY B, RUSSELL AS, MAKSYMOWYCH WP: Survival analysis of treatment with leflunomide, combination leflunomide/methotrexate, and infliximab for rheumatoid arthritis in routine clinical practice. Presented at The 68th Annual Meeting of the American College of Rheumatology (2003): Abstract 793.
   Google Scholar
• TA KT, CARTWRIGHT V, MICHAUD K, WOLFE F: Safety data comparing combination therapy of leflunomide plus methotrexate to leflunomide alone: a five-year prospective study. Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 288.
   Google Scholar
• DOUGADOS M, EMERY P, LEMMEL EM, ZERBINI CAF, BRIN S, VAN RIEL P: When a DMARD fails, should patients switch to sulfasalzine or add sulfasalazine to continuing leflunomide? Ann. Rheum. Dis. (2005) 65:44–51.
   Google Scholar
• GODINHO F, GODFRIN B, EL MAHOU S, NAVAUX F, ZABRANIECKI L, CANTAGREL A: Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin. Exp. Rheumatol. (2004) 22(3):328–330.
   PubMed Web of Science ®Google Scholar
• HANSEN KE, CUSH J, SINGHAL A et al.: The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. (2004) 51(2):228–232.
   PubMed Web of Science ®Google Scholar
• PERDRIGER A, COMBE B, KUNTZ JJ et al: A French multicenter retrospective study on the efficacy and safety of infliximab in association with DMARDs other than methotrexate. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract 5AT0356.
   Google Scholar
• FLENDRIE M, CREEMERS MC, WELSING PM, VAN RIEL PL: The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (2004) [Epub ahead of print].
   Google Scholar
• ANTONI C, NOSSLEIN HG, WOLLENHAUPT J, BURMESTER GR, KROGER K, KALDEN JR: Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Presented at The Annual European Congress of Rheumatology EULAR 2004 (2004): Abstract FRI0093.
   Google Scholar
• STRUPPLER CI, THIES W, SCHATTENKIRCHNER M, KELLNER H: Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis (RA) patients. Presented at The Annual European Congress of Rheumatology EULAR 2002 (2002): Abstract AB0157.
   Google Scholar
• KIELY PDW, JOHNSON DM: Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (2002) 41(6):631–637.
   PubMed Web of Science ®Google Scholar
• MARIETTE X, BIJLSMA JWJ, HEROLD M, EISELSTEIN J, SPENCER-GREEN GT, KUPPER H: Efficacy evaluation of adalimumab (Humira®) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial. Presented at The Annual European Congress of Rheumatology EULAR 2004(2004): Abstract FRIOO99.
   Google Scholar
• FURST DE, SCHIFF MH, FLEISCHMANN RM et al: Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol (2003) 30(12):2563–2571.
   PubMed Web of Science ®Google Scholar
• TESSER J, FELSICHMANN R, DORE R et al.: Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. Rheumatol (2004) 31(4):649–654.
   Web of Science ®Google Scholar
• TASSIULAS I, DUNCAN SR, CENTOLA M, THEOFILOPOULOS AN, BOUMPAS DT: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum. Immunol (1999) 60(6):479–491.
   PubMed Web of Science ®Google Scholar
• LIANG GC, BARR WG: Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J. Clin. Rheumatol (2001) 7(6):366–370.
   PubMed Web of Science ®Google Scholar
• REICH K, HUMMEL KM, BECKMANN I, MOSSNER R, NEUMANN C: Treatment of severe psoriasis and psoriatic arthritis with leflunomide. BE J. Dermatol. (2002) 146(2):335–336.
   PubMed Web of Science ®Google Scholar
• TLACUILO-PARRA JA, GUEVARA-GUTIERREZ E, RODRIGUEZ-CATELLANOS MA, ORNELAS-AGUIRRE JM, BARBRA-GOMEZ JF, SALAZAR-PARAMO M: Leflunomide in the treatment of psoriasis: results of a Phase II open trial. Br. J. Dermatol (2004) 150(5):970–976.
   PubMed Web of Science ®Google Scholar
• THAMI G, GARG G: Leflunomide in psoriasis and psoriatic arthritis: a preliminary study. Arch. Dermatol (2004) 140(10):1288–1289.
   PubMed Web of Science ®Google Scholar
• KALTWASSER JP, NASH P, GLADMAN D et al: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. (2004) 50(6):1939–1950.
   PubMed Web of Science ®Google Scholar
• ••A Phase III trial of leflunomide in thetreatment of PsA.
   Google Scholar
• CLEGG DO, REDA DJ, MEJIAS E et al:Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum. (1996) 39(12):2013–2020.
   PubMed Web of Science ®Google Scholar
• SILVERMAN E, SPIEGEL L, JUNG LK et al: Efficacy and safety of leflunomide (LEF) versus methotrexate (IVITX) in the treatment of pediatric patients with juvenile rheumatoid arthritis (JRA). Presented at The 68th Annual Meeting of the American College of Rheumatology (2003): Poster 511.
   Google Scholar
• SILVERMAN E, MOUY R, SPIEGEL L et al: Durability of efficacy, safety, and tolerability of leflunomide (LEF) or methotrexate (IVITX) over 48 weeks of treatment in pediatric patients with juvenile rheumatoid arthritis (JRA). Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 72.
   Google Scholar
• HAIBEL H, RUDWALEIT M, BRAUN J, SIEPER J. Six months open label trial of leflunomide in ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64(1):124–126.
   PubMed Web of Science ®Google Scholar
• VAN DENDEREN JC, VAN DER PAARDT M, NURMOHAMED MT, DE RYCK YM, DIJKMANS BAC, VAN DER HORST-BRUINSMA IE: Double-blind, randomized, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Presented at The Annual European Congress of RheumatologyEULAR 2004(2004): Abstract 5AT0033.
   Google Scholar
• METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (2004) 43(3):315–320.
   PubMed Web of Science ®Google Scholar
• REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus (2001) 10(7)480–483.
   Google Scholar
• TAM L-S, LI EK, WONG C-K, LAM CW, SZETO C-C: Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus (2004) 13(8):601–604.
   PubMed Web of Science ®Google Scholar
• PRAJAPATI DN, KNOX JF, EMMONS J, SAEIAN K, CSUKA ME, BINION DG: Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J. Clin. Castroenterol (2003) 37(2):125–128.
   PubMed Web of Science ®Google Scholar
• SCAGLIUSI P, D'AMORE M, SCAGLIUSI A, MINENNA G: Le nuove terapie nella syndrome di SjOgren: efficacia della leflunomide. Reumatismo. (2004) 56 (3 Suppl. 3):271 (Abstract PO4).
   Google Scholar
• BENUCCI M, LI GOBBI F, PIERFEDERICI P: Modificazioni dei parametric della scintigrafia delle ghiandole salivary in corso di terapia con leflunomide in pazienti con syndrome di SjOgren. Reumatismo (2004) 56(3; Suppl. 3):324 (Abstract P112).
   Google Scholar
• SCHADLICH PK, ZEIDLER H, ZINK A et al.: Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany. Z Rheumatol (2004) 63(1):59–75.
   PubMed Web of Science ®Google Scholar
• OLLENDORF DA, PETERSON AN, DOYLE J, HUSE DM: Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am. J. Manag. Care (2002) 8(7 Suppl.):5203–5213.
   Google Scholar
• CANNON GW, STRAND V, OED C, SCARAZZINI L, HOLDEN WL: Adverse events during clinical trials comparing leflunomide, methotrexate, sulfasalazine and placebo. Meta-analysis of data from Phase II and III controlled clinical trials. Presented at The Annual European Congress of RheumatologyEULAR 2004(2004): Abstract and poster FRIOO14.
   Google Scholar
• UJFALUSSY I, KOO E, SESZTAK M, GERGELY P: Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheumatol. (2003) 62(2):155–160.
   Google Scholar
• WHITING-O'KEEFE QE, FYE KH, SACK KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. (1991) 90(6):711–716.
   Google Scholar
• CANNON GW, HOLDEN WL, JUHAERI J, DAI W, SCARAZZINI L, STANG P: Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. ./. Rheumatol. (2004) 31(10):1906–1911.
   PubMed Web of Science ®Google Scholar
• ••A study of DMARD safety based on datafrom a US insurance claims database.
   Google Scholar
• CANNON GW, STRAND V, SCARAZZINI L, HOLDEN WL: Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate between September 1998 and June 2003. Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 291.
   Google Scholar
• VAN ROON EN, JANSEN TL, HOUTMAN NM, SPOELSTRA P, BROUWERS JR: Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Sal (2004) 27(5):345–352.
   PubMed Web of Science ®Google Scholar
• SUISSA S, ERNST P, HUDSON M, BITTON A, KEZOUH A: Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am. J. Med. (2004) 117(2):87–92.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Hotline. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis part III: safety and efficacy update on leflunomide (Arava® 2003).
   Google Scholar
• CANNON GW, STRAND V, SIMON LS et al.: Interstitial lung disease in rheumatoid arthritis patients receiving leflunomide. Presented at The 69th Annual Meeting of the American College of Rheumatology (2004): Poster 292.
   Google Scholar
• ITO S, SUMIDA T. Interstitial lung diseaseassociated with leflunomide. Intern. Med. (2004) 43(12):1103–1104.
   PubMed Web of Science ®Google Scholar
• BRENT RL: Teratogen update: reproductive risks of leflunomide (AravaTm); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology (200 1) 63(2) :106–112.
   Google Scholar
• CHAKRAVARTY EF, SANCHEZ-YAMAMOTO D, BUSH TM: The use of disease-modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. Rheumatol (2003) 30(2):241–246.
   Web of Science ®Google Scholar